Nuwellis, Inc. (NASDAQ:NUWE) Stock Short Interest Report for October

Nuwellis, Inc. (NASDAQ:NUWE – Get Free Report) saw a large increase in short interest in October. As of October 30th, there was short interest totaling 195,586 shares, an increase of 118.9% from the October 15th total of 89,357 shares. Approximately 36.8% of the company’s shares are sold short. Based on an average trading volume of 3,723,204 shares, the days-to-cover ratio is presently 0.1 days.

Analysts Set New Price Targets

Several brokerages have recently issued reports on NUWE. Weiss Ratings reissued a “sell (e+)” rating on shares of Nuwellis in a research report on Monday, September 21st. Wall Street Zen cut shares of Nuwellis from a “hold” rating to a “sell” rating in a report on Saturday. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Read Our Latest Stock Analysis on NUWE

Nuwellis Stock Performance

Shares of NASDAQ NUWE opened at $4.90 on Monday. The stock has a market cap of $2.65 million, a P/E ratio of -0.00 and a beta of 0.03. Nuwellis has a 12-month low of $2.52 and a 12-month high of $1,556.07. The business’s fifty day simple moving average is $6.03 and its 200-day simple moving average is $206.53.

Nuwellis (NASDAQ:NUWE – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($5.81) EPS for the quarter, topping the consensus estimate of ($122.85) by $117.04. Nuwellis had a negative return on equity of 414.75% and a negative net margin of 150.50%. The firm had revenue of $2.21 million during the quarter, compared to analysts’ expectations of $2.50 million.

About Nuwellis

(Get Free Report)

Nuwellis, Inc. is a medical device company focused on fluid management therapies for patients with fluid overload. The company develops and commercializes ultrafiltration technologies designed to remove excess salt and fluid from the blood when conventional diuretic therapy may be inadequate or poorly tolerated. Nuwellis’ principal product is the Aquadex system, including the Aquadex FlexFlow system, a compact ultrafiltration platform used in hospital settings. The system is intended for temporary extracorporeal fluid removal in patients with conditions such as fluid overload associated with heart failure, renal dysfunction, and other critical-care needs.

See Also

Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.